DEA Places Cannabinoid Into Schedule II
The Drug Enforcement Administration is placing the newly approved drug lasmiditan in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective Jan. 31, lasmiditan, which was granted approval by the Food and Drug Administration in October, is subject to new registration, labeling, recordkeeping, and import and export requirements. DEA is accepting comments on the rule until March 2.
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
(Federal Register 01/31/20)